AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

NORTH CHICAGO, Ill.,Oct. 13, 2025/PRNewswire/ -- AbbVie (NYSE:ABBV) today announced it will unveil new data from its robust antibody-drug conjugate (ADC) platform at the 2025 European Society for Medical Oncology (ESMO) Congress, taking place October 17-21, in Berlin, Germany. Data from investigational and approved ADCs across AbbVie's portfolio such as telisotuzumab adizutecan (Temab-A),1-3ABBV-706,4,5and Emrelis™ (telisotuzumab vedotin),6in patients with difficult-to-treat tumor types where there is urgent need for additional treatment options,7-15will be featured in multiple presentations.

"Despite recent progress in the treatment of advanced solid tumors, patients still face limited options and pressing unmet needs," said Daejin Abidoye, M.D., vice president, therapeutic area head, oncology, solid tumor and hematology, AbbVie. "The compelling data we are sharing at ESMO showcases how we are advancing targeted therapies across a range of solid tumors and highlights the potential of our portfolio."

Key highlightsAbbVie will presentthree oral presentationsforTemab-A, a next-generation, investigational c-Met directed ADC with a novel topoisomerase 1 inhibitor (Top1i) payload. Phase 1 results with Temab-A both as a monotherapy and in combination across advanced, solid tumors will be presented:

"Temab-A continues to show meaningful clinical activity across an expanding range of solid tumors and patient populations, including patients withMET-amplification and increased c-Met expression as we have seen in previously presented data," said Vivek Subbiah, M.D., Chief, Early-Phase Drug Development, Sarah Cannon Research Institute and Temab-A investigator. "These data reinforce Temab-A's potential in multiple solid tumors and thereby warrant its further clinical investigation."

AbbVie will also present new analysis from a Phase 1 study ofABBV-706, a SEZ6-directed ADC with a Top1i payload,in relapsed/refractorysmall cell lung cancer (R/R SCLC)(NCT05599984).

A Phase 2 study assessing ABBV-706 in combination with atezolizumab as replacement of platinum-based chemotherapy is currently ongoing (NCT07155174) in 1L SCLC.

Details on key presentations at the ESMO 2025 Congress are available below and the full abstracts are available via theESMO online program.

Sunday,October 19

2:45 - 4:15 PMCEST

Oral presentation

Proffered papersession:Developmentaltherapeutics

Room: BremenAuditorium - Hall6.2

Sunday,October 19

2:45 - 4:15 PMCEST

Mini oral session1: GI tumors,lowerdigestive

Room:

Cologne Auditorium- CityCube A

Monday,October 20

8:30 – 10:00AM CEST

Mini oral session2: GI tumours,upper digestive

Room: BonnAuditorium - Hall7.1c

Saturday,October 18

12:00 – 12:45PM CEST

Saturday,October 18

12:00 – 12:45PM CEST

Sunday,October 19

12:00 – 12:45PM CEST

Saturday,October 18

12:00 – 12:45PM CEST

Saturday,October 18

12:00 – 12:45PM CEST

Saturday,October 18

12:00 – 12:45PM CEST

Saturday,October 18

12:00 – 12:45PM CEST

Saturday,October 18

12:00 – 12:45PM CEST

Saturday,October 18

12:00 – 12:45PM CEST

Telisotuzumab adizutecan (Temab-A) and ABBV-706 are investigational medicines and are not approved by any health authorities worldwide. The safety and efficacy of these investigational medicines are under evaluation as part of ongoing clinical studies.

Elahere™ (mirvetuximab soravtansine)and Emrelis™(telisotuzumab vedotin) are approved medicines being investigated for additional uses. Safety and efficacy have not been established for these unapproved additional uses.

Additional information on AbbVie clinical trials is available athttps://www.clinicaltrials.gov/.

U.S. Prescribing Information for AbbVie Medicines

Please see fullPrescribing informationfor ELAHERE™ (mirvetuximab soravtansine-gynx)Please see fullPrescribing Informationfor EMRELIS™(telisotuzumab vedotin-tllv)

About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us atwww.abbvie.com. Follow @abbvie onLinkedIn,Facebook,Instagram,X (formerly Twitter)and YouTube.

About AbbVie in OncologyAbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.

Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visithttp://www.abbvie.com/oncology.

Forward-Looking StatementsSome statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References: